immunization (tumor vaccine) and adoptive immunotherapy (10) would be definitely required for utilization of adoptive immunotherapyfor lung cancer. and tumor necrosis factor (TNF) for immunotherapy. Another approach is the utilization ofhematopoietic growth factors such as granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) for the recovery of bone marrowfailure caused by aggressive chemotherapy. Both approaches can be used especially for the treatment of advanced or disseminated cancers which are not indicated for surgical therapy, as therapy of inoperable cancer requires new treatment strategies. Here, we present the fundamental and clinical results obtained using the above approaches.
1. Immunochemotherapyof advanced gastrointestinal cancers using interleukin 2 (IL-2), cyclophosphamide and biological response modifier (BRM).
To augment the effect of IL-2, we additionally used the anticancerous agents (cyclophosphamide) and BRM(PSK; KrestinR). Cyclophosphamide was used both for the improvement of the immunosuppressive condition of cancer bearers and for the accumulation of IL-2 activated anticancer effector cells such as natural killer cells and cytotoxic T-cells to tumor tissues. PSK, which has been known as an immunostimulating agent derived from the myceliumof Coriolus vesicolor, was used for the neutralization of soluble immunosuppressive factors and for the induction of killer cells (1) . It is assumed that the anticancerous immunenetwork is further augmentedby the combinationsof these three agents.
Prior to the humanstudy, animal experiments using Balb/c mice carrying B16 melanomacells were conducted. B16 melanomacells were subcutaneously transplanted into the hind limb and the number of pulmonary metastases and the survival rate were examined (2) . Comparing the non-treated group and the IL-2 and cyclophosphamide-treated group, the latter showed Cytokine-Combined Chemoimmunotherapy metastases and elongation of survival. Wethen started the clinical pilot study using the three drug combination immunochemotherapy (3). All of the patients gave informed, written consent to the trial. Cyclophosphamide was intravenously administered at a dose of 600mg/m2 every week and PSK (2g/day) was taken orally every day. IL-2 (TGP-3, 2,000 units/day) was administered through a central venous catheter for 4 weeks. This 4-week treatment cycle was repeated at least twice and the clinical effect was then evaluated. Table  1 shows patients characteristics and their treatment effect. All the seven patients suffered from gastrointestinal malignancies which were not indicative for surgical treatment. A complete response (CR) was obtained in a patient with a metastatic liver tumor from gallbladder carcinoma (4), and two patients with colon carcinoma and hepatocellular carcinoma responded partially. A remarkable decrease in ascitic fluid was obtained in a patient with pancreatic carcinoma. A decrease in tumor markers such as oc-fetoprotein (AFP) and carcinoembryonic proteins (CEA) were observed in two patients. Immunological improvements inducing the decrease of serum immunosuppressive factors (IAP; immunosuppressive acidic protein and IS; immunosuppressive substance) and an increase of killer cell activity were noted.
2. Recovery of chemotherapy-induced bone marrow failure by granulocyte colony stimulating factor and peripheral blood stem cell transplantation Anotherapproachof cytokine application for cancer chemotherapy is the use of hematopoietic growth factors and stem cells for the rapid recovery of bone marrowfailure after highdose anticancer chemotherapy. The diseases indicated for this treatment strategy are "chemotherapy-curable tumors" including leukemia, malignant lymphoma, germ cell tumors, breast cancer, and ovarian carcinomas. -Wepresently are using G-CSF and peripheral blood stem cells (PBSC) for the recovery of chemotherapy-induced bone marrow failure (5) . PBSC are efficiently mobilized into circulation after chemotherapyand/ or G-CSFadministration (6) . Whenpatients were treated with chemotherapy and then administered with G-CSF and PBSCs, which are confirmed by colony forming unit-granulocyte macrophage (CFU-GM) colony assay and by flow cytometry using anti-CD34 monoclonal antibody, are mobilized. The important issue to be resolved about PBSCis whether PBSChas a long standing hematopoietic ability as does bone marrow stem cells and whether the tissue distribution ofPBSCis the same as bone marrowstem cells. CD34positive mononuclear cells were prepared from the patient' stem cells derived from both bone marrow and peripheral blood by using an Isolex 50 column and were transfected with neomycin-resistant (neo) gene-carrying retrovirus vector in the presence ofinterleukin-3 and interleukin-6. The CD34positive cells marked with neo-gene were administered to severe combined immunodeficiency (SCID) mice through the tail vein, and the inserted neo-gene was then examined serially by the polymerase chain reaction (PCR) procedure. It was noted that the neogene was detected in the peripheral blood, as well as in the bone marrow, liver and spleen, even 24 weeks after PBSCinoculation, suggesting that PBSC has a long-lasting capability for hematopoiesis. In addition, the neo-gene of PBSCappeared in the circulation faster than that of bone marrowstem cells (6) . These results confirm tumor (according to National Cancer Institute risk criteria) with a high dose chemotherapy protocol using carboplatin (400 mg/ m2/day -5 to -3), VP 16 (400 mg/m2/day -5 to -3), ifosphamide (2.5 g/m2/day -5 to -3), PBSC transplantation (day 0) and G-CSF administration (from days 0 to 14). It is known that these patients usually die within 24 months if the conventional (regular-dose) chemotherapy is undertaken. The clinical effect of this therapy revealed 2 CRs and 3 PRs (Table 2 ) and the 40-months survival was 60%by Kaplan-Meier analysis, which was very effective. Further application of this treatment is promising if more treatment regimens for curing other cancers are established.
